Despite these limitations, the meta-analysis accomplished our goal of assessing the repeatability and inferring the magnitude of CYP2C19 change across a variety of other NAFLD cohorts. This evidence concerns the gene CYP2C19 and metabolic dysfunction-associated steatotic liver disease.